

chain nodes :

10 11 12 13 14 23 24 26 27 28 30 31 32

ring nodes :

1 2 3 4 5 6 7 8 9 16 17 18 19 20 21

chain bonds :

4-10 5-11 8-31 9-30 11-12 11-13 13-14 14-18 16-27 17-28 19-23 20-24
21-26 31-32

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 16-17 16-21 17-18 18-19 19-20
20-21

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-10 5-6 9-30 11-12 11-13 13-14 16-27 17-28 19-23
20-24 21-26

exact bonds :

2-7 3-9 5-11 7-8 8-9 8-31 14-18 31-32

normalized bonds :

16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :

containing 1 :

G1:H,Cl,Br,F,CN,NO2,C

G2:C,H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 23:CLASS 24:CLASS 26:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS
32:CLASS

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR



G1 H, Cl, Br, F, CN, NO2, C

G2 C, H

Structure attributes must be viewed using STN Express query preparation.

=> s l3 ful

FULL SEARCH INITIATED 09:02:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1294 TO ITERATE

100.0% PROCESSED 1294 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

L4 14 SEA SSS FUL L3

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

312.31

FILE 'CAPLUS' ENTERED AT 09:02:24 ON 03 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Sep 2004 VOL 141 ISS 11

FILE LAST UPDATED: 2 Sep 2004 (20040902/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l4

L5 3 L4

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 2004:203665 CAPLUS
 DOCUMENT NUMBER: 140:229446
 TITLE: Method using heterocyclic carboxamide compounds for preventing or treating atherosclerosis or restenosis
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2004102473	A1	20040527	US 2003-651216	20030828
PRIORITY APPLN. INFO.:			US 2002-407090P	P 20020830


OTHER SOURCE(S): MARPAT 140:229446
 AB The invention provides a method of treating atherosclerosis or restenosis in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-i]quinoline carboxamide derivative
 IT 292143-78-3 292143-85-2 292143-86-3
 292143-94-3 292144-00-4 292144-31-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heterocyclic carboxamide compds. for preventing or treating atherosclerosis or restenosis)

RN 292143-78-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 292143-85-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-hydroxybutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-86-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-94-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 292144-00-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-31-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2-diethylaminoethyl)-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:646018 CAPLUS
 DOCUMENT NUMBER: 133:222607
 TITLE: Preparation of 5-carboxamides as antiviral agents
 INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Scott, Allen
 PATENT ASSIGNEE(S): Pharmacia and Upjohn Company, USA
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053610	A2	20000914	WO 2000-US5937	20000307
WO 2000053610	A3	20010125		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6239142	B1	20010529	US 2000-521027	20000307
NZ 513758	A	20010928	NZ 2000-513758	20000307
EP 1159279	A2	20011205	EP 2000-913786	20000307
EP 1159279	B1	20021016		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000008604	A	20020416	BR 2000-8804	20000307
AT 226208	E	20021115	AT 2000-913786	20000307
JP 2002539130	T2	20021119	JP 2000-604046	20000307
ES 2184705	T3	20030416	ES 2000-913786	20000307
AU 759875	B2	20030501	AU 2000-35162	20000307
AU 2000035162	A5	20000928		
US 2002006937	A1	20020117	US 2001-824334	20010402
US 6495683	B2	20021217		
ZA 2001007255	A	20021202	ZA 2001-7255	20010831
NO 2001004363	A	20011108	NO 2001-4363	20010907
PRIORITY APPLN. INFO.:			US 1999-123660P	P 19990309
			US 2000-521027	A3 20000307
			WO 2000-US5937	W 20000307

OTHER SOURCE(S): MARPAT 133:222607
 GI

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I; R1 = Cl, Br, CN, etc.; R2 = H, R5, NR7R8, etc.; R3 =

H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.; R5 = heterocyclyl bound via a carbon atom, (un)saturated (un)substituted alkyl, (un)saturated (un)substituted cycloalkyl, etc.; R7, R8 = H, aryl, (un)saturated (un)substituted alkyl; NR7R8 form a heterocyclyl] and their pharmaceutically acceptable salts, useful in preventing or treating a herpesvirus infection, were prepared Thus, reacting Et

4-hydroxythieno[2,3-b]pyridine-5-carboxylate with 4-chlorobenzylamine afforded 45% I [R1 =

Cl;

R2 = H; R3, R4 = H] which showed IC50 of 28.9 μM against HCMV polymerase.

IT 292143-78-3P 292143-85-2P 292143-86-3P

292143-88-5P 292143-94-3P 292144-00-4P

292144-31-1P

RI: BAC (Biological activity or effector, except adverse); BSU

(Biological study); SPN (Synthetic preparation); THU (Therapeutic use);


RIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as

antiviral agents)

RN 292143-78-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292143-85-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-hydroxybutyl)-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 292144-00-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7,7-dihydro-2-(3-hydroxypropyl)-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-31-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[2-(diethylamino)ethyl]-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 292143-86-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292143-88-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[2-(diethylamino)ethyl]-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 292143-94-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1991:632279 CAPLUS

DOCUMENT NUMBER: 115:232279

TITLE: Preparation of 7-(biphenylmethyl)-4-oxothieno[2,3-b]pyrimidine-5-carboxylates as angiotensin II

antagonists

INVENTOR(S): Morimoto, Akira; Nishikawa, Kohei; Naka, Takehiko

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 47 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 443568	A1	19910828	EP 1991-102513	19910221
EP 443568	B1	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2036618	AA	19910823	CA 1991-2036618	19910219
CA 2036618	C	20021029		
JP 07061986	A2	19950307	JP 1991-27273	19910221
JP 3035745	B2	20000424		
AT 139233	E	19960615	AT 1991-102513	19910221
US 5284661	A	19940208	US 1993-47368	19930419
PRIORITY APPLN. INFO.:			JP 1990-42125	A 19900222
			JP 1991-3958	A 19910117
			US 1991-657051	B1 19910219

OTHER SOURCE(S): MARPAT 115:232279

GI



L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AB Title compds. [I; R1, R2 = H, halo, cyano, NO2, acylamino, (substituted)
 hydrocarbyl; R3 = H, (substituted) alkyl, alkenyl, COX; X = H, alkoxy,

OH,
 halo, amino; R4 = H, halo, NO2; R5 = residue capable of forming an anion
 or convertible to an anion; R6 = H, (substituted) alkyl, alkenyl; R7 =
 (substituted) hydrocarbyl; A = bond, spacer group; n = 1,2; W = CR3:CR6,
 NR7CO], were prepared. Thus, Et 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-
 carboxylate, 4-(2'-cyanophenyl)benzyl chloride, and K2CO3 were stirred at
 90° for 2 h to give 60% coupling product, which was stirred with
 NaN3 and NH4Cl in DMF at 110° to give 13% title compound II. Several
 I at 30 mg/kg orally in rats inhibited the pressor response of

angiotensin

II by ≥70%. Tablets were prepared containing II.

IT 137069-72-8P 137069-83-1P 137069-84-2P

137069-85-3P 137069-86-4P 137069-88-6P

137069-89-7P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as angiotensin II antagonist)

RN 137069-72-8 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-4,7-dihydro-4-oxo-N-(
 phenylmethyl)-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
 (9CI) (CA INDEX NAME)



RN 137069-83-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-N-[(4-fluorophenyl)methyl]-
 4,7-dihydro-4-oxo-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
 (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 137069-84-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-N-[(3-fluorophenyl)methyl]-
 4,7-dihydro-4-oxo-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
 (9CI) (CA INDEX NAME)



RN 137069-85-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-4,7-dihydro-4-oxo-N-(1-
 phenylethyl)-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
 (CA INDEX NAME)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 137069-86-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-N-[(2-fluorophenyl)methyl]-
 4,7-dihydro-4-oxo-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
 (9CI) (CA INDEX NAME)



RN 137069-88-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-4,7-dihydro-N-[(4-
 methylphenyl)methyl]-4-oxo-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-
 yl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 137069-89-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-ethyl-4,7-dihydro-N-[(2-
 methylphenyl)methyl]-4-oxo-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-
 yl]methyl]- (9CI) (CA INDEX NAME)

